文献速递眼底病与葡萄膜炎

阿达木单抗治疗活动性非感染性中间、后段及全葡萄膜炎在实际临床实践中的影响:HOPE研究

Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study.
PubMed 文献 · Br J Ophthalmol · 2023-11-22

这项前瞻性观察性研究纳入149例活动性非感染性中间、后段或全葡萄膜炎成人患者,接受阿达木单抗治疗并随访12个月。任意随访时点91%(129/141)患者达到静止,无皮质类固醇静止比例从35%升至52%,维持应答比例从63%升至76%,因葡萄膜炎就诊比例从89%降至21%,未观察到新安全性信号。

要点

  • 任意随访时点91%(129/141)患者达到静止(前房细胞和玻璃体混浊均≤0.5+且无新活动性脉络膜视网膜病灶)。
  • 无皮质类固醇静止比例从V1的35%(51/147)升至V4的52%(67/128),p<0.05。
  • 因葡萄膜炎就诊比例从基线89%(132/149)降至V4的21%(27/127),未观察到新安全性信号。

核心结论

  • 结果表明阿达木单抗可改善活动性非感染性中间、后段及全葡萄膜炎患者的生活质量并减轻经济负担。

研究设计与样本

  • 前瞻性观察性研究,2017年6月至2020年4月纳入149例接受阿达木单抗治疗的活动性非感染性中间、后段或全葡萄膜炎成人患者,随访12个月。

主要发现

  • 任意随访时点达到静止的患者为129/141(91%)。
  • V1至V4各访视达到静止的患者分别为99/145(68%)、110/142(77%)、102/131(78%)和99/128(77%)。
  • 无皮质类固醇静止患者从V1的51/147(35%)增至V4的67/128(52%),p<0.05。
  • 维持应答患者从V2的89/141(63%)增至V4的92/121(76%),p<0.05; flare患者从V1的25/145(17%)降至V4的13/128(10%),p=0.092。
  • 因葡萄膜炎就诊患者从V0的132/149(89%)降至V4的27/127(21%),工作能力和视觉功能在整个研究期间改善,未观察到新安全性信号。

关键数值与推荐

  • 主要终点为任意随访时点达到静止(前房细胞分级和玻璃体混浊分级在双眼均≤0.5+,无新活动性脉络膜视网膜病灶)的患者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIM: This study evaluated real-life adalimumab impact in patients with active non-infectious intermediate, posterior, or panuveitis (NIIPPU). METHODS: Adults with active NIIPPU received adalimumab in this prospective, observational study (06/2017-04/2020). Patients were evaluated at baseline (V0) and four follow-up visits over 12 months (V1-V4). PRIMARY ENDPOINT: proportion of patients achieving quiescence (anterior chamber (AC) cells grade and vitreous haze (VH) grade≤0.5+ in both eyes, no new active chorioretinal lesions) at any follow-up visit. Secondary endpoints: proportion of patients achieving quiescence at each visit; proportion of patients maintaining response; and proportion of patients with flares. Workability, visual function, healthcare resource utilisation, and safety were evaluated. RESULTS: Full analysis set included 149 patients. Quiescence at any follow-up visit was achieved by 129/141 (91%) patients. Quiescence at individual visits was achieved by 99/145 (68%), 110/142 (77%), 102/131 (78%), and 99/128 (77%) patients at V1-V4, respectively. Number of patients in corticosteroid-free quiescence increased from 51/147 (35%; V1) to 67/128 (52%; V4; p<0.05). Proportion of patients with maintained response increased from 89/141 (63%; V2) to 92/121 (76%; V4; p<0.05) and proportion of patients with flare decreased from 25/145 (17%; V1) to 13/128 (10%; V4; p=0.092). Workability and visual function improved throughout the study. Proportion of patients with medical visits for uveitis decreased from 132/149 (89%; V0) to 27/127 (21%; V4). No new safety signals were observed. CONCLUSION: These results demonstrated adalimumab effectiveness in improving quality of life while reducing economic burden of active NIIPPU.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Pleyer U, Al-Mutairi S, Murphy CC, et al. Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study. Br J Ophthalmol. 2023. PMID: 36261259. doi:10.1136/bjo-2021-320770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。